1999
DOI: 10.1016/s0959-8049(99)00012-x
|View full text |Cite
|
Sign up to set email alerts
|

Prognostic factors in urothelial renal pelvis and ureter tumours: a multicentre Rare Cancer Network study

Abstract: To assess the prognostic factors in patients with transitional-cell carcinoma of the renal pelvis and/or ureter, a series of 138 patients with transitional-cell carcinoma of the renal pelvis and/or ureter was collected in a retrospective multicentre study. 12 patients with distant metastases were excluded from the statistical evaluation. All but 3 patients underwent radical surgery: nephroureterectomy (n = 71), nephroureterectomy and lymphadenectomy (n = 20), nephroureterectomy and partial bladder resection or… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

7
82
1
5

Year Published

2006
2006
2017
2017

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 155 publications
(95 citation statements)
references
References 22 publications
7
82
1
5
Order By: Relevance
“…Similar observations have been made in other studies, 8,11,12,[15][16][17][22][23][24] whereas only one investigation has identified tumor grade as an independent predictor of overall survival, but not of cancer-specific survival in patients with upper tract cancer. 18 The new two-tiered grading system, however, has only twice before been applied with respect to prognostic impact in upper urinary tract tumors.…”
Section: Discussionsupporting
confidence: 89%
See 2 more Smart Citations
“…Similar observations have been made in other studies, 8,11,12,[15][16][17][22][23][24] whereas only one investigation has identified tumor grade as an independent predictor of overall survival, but not of cancer-specific survival in patients with upper tract cancer. 18 The new two-tiered grading system, however, has only twice before been applied with respect to prognostic impact in upper urinary tract tumors.…”
Section: Discussionsupporting
confidence: 89%
“…5,8,[10][11][12][13][15][16][17]20,22,24,25 Regarding pT3 pelvic cancer, our data demonstrating significantly poorer outcome of patients with UCs showing macroscopic parenchyma and/or fat invasion compared with patients with UCs showing microscopic parenchyma invasion only are in line with two previous studies. 35,36 They reported that pT3 UCs with extensive parenchymal invasion (defined as invasion deeper than 5 mm) had a prognosis similar to that of pT4 tumors, whereas pT3 UCs without extensive parenchymal invasion (including cases with intraductal spread only) had a prognosis similar to that of pT1/pT2 disease.…”
Section: Discussionsupporting
confidence: 88%
See 1 more Smart Citation
“…[1][2][3][4][5] The pathological T and N categories and pathologically defined tumor grade are powerful indicators of prognosis. [6][7][8][9][10][11] However, to date, the ability of the combined input from pathological stage, grade, and other tumor and patient characteristics has never been examined with respect to prediction of cancer-specific mortality after nephroureterectomy. In the current study, we hypothesized that, like in other malignancies, pT and pN stages combined with tumor grade and patient characteristics, such as age and sex, could highly accurately predict the probability of cancerspecific mortality.…”
mentioning
confidence: 99%
“…3 The knowledge of prognostic factors for UUT-TCC often is based on studies on the most common bladder TCC, and only a few studies on prognostic factors for UUT-TCC have been published to date, and those sometimes have reported conflicting data. Tumor stage [4][5][6][7][8][9][10][11] and histologic grade 7,11,12 are among the best established prognostic factors; whereas, conversely, the roles of other potentially relevant variables, such as a history of bladder cancer, tumor site, lymphovascular invasion, or multifocality, are less clear. [6][7][8]10,11 A clear knowledge of those prognostic data would be useful for counseling patients after surgery and for identifying those patients with unfavorable cancer-related outcome who may be candidates for future neoadjuvant or adjuvant randomized controlled trials.…”
mentioning
confidence: 99%